Effect of enterokinetic prucalopride on intestinal motility in fast rats

World Journal of Gastroenterology

Volumn 9, Issue 9, 2003, Pages 2065-2067

  Qi, Hui Bin ^a   Luo, Jin Yan ^a   Liu, Xin ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHARCOAL; CISAPRIDE; PRUCALOPRIDE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GASTROINTESTINAL MOTILITY; INTESTINE MOTILITY; MALE; MEASUREMENT; NONHUMAN; RAT;

EID: 0141718395     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v9.i9.2065     Document Type: Article

References (32)

1. Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. Characterization of the receptors involved in the 5-HT-induced excitation of canine antral longitudinal muscle. Br J Pharmacol 2001; 134: 1351-1359
2. Leclere PG, Lefebvre RA. Presynaptic modulation of cholinergic neurotransmission in the human proximal stomach. Br J Pharmacol 2002; 135: 135-142
3. Prins NH, Van Der Grijn A, Lefebvre RA, Akkermans LM, Schuurkes JA. 5-HT(4) receptors mediating enhancement of contractility in canine stomach; An in vitro and in vivo study. Br J Pharmacol 2001; 132: 1941-1947
4. Briejer MR, Prins NH, Schuurkes JA. Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs. Neurogastroenterol Motil 2001; 13: 465-472
5. Jin JG, Foxx-Orenstein AE, Grider JR. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J Pharmacol Exp Ther 1999; 288: 93-97
6. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999; 44: 682-686
7. Poen AC, Felt-Bersma RJ, Van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999; 13: 1493-1497
8. Briejer MR, Schuurkes JA, Sarna SK. Idiopathic constipation: Too few stools and too little knowledge. Trends Pharmacol Sci 1999; 20: 1-3
9. Li FJ, Zhou YY, Zhang XC, Shen SR. A postprandial manometric recording of sigmoid motor activity in patients with idiopathic colonic constipation. Shijie Huaren Xiaohua Zazhi 2002; 10: 1232-1233
10. Rao SS, Sadeghi P, Batterson K, Beaty J. Altered periodic rectal motor activity: A mechanism for slow transit constipation. Neurogastroenterol Motil 2001; 13: 591-598
11. Zhang WW, Li Y. Psychiatric and psychologic factors of functional gastrointestinal disorders. Shijie Huaren Xiaohua Zazhi 2002; 10: 1324-1328
12. Tian B, Yang SL, Li YH, Duan QH, Chen GT, Li F, Ma SF. Pathological changes and clinical significance of colonic myenteric plexus in patients with slow transit constipation. Shijie Huaren Xiaohua Zazhi 2000; 8: 1385-1388
13. Yu DH. Suggestions on surgical treatment of constipation. Shijie Huaren Xiaohua Zazhi 1999; 7: 169-170
14. Gao F, Zhang SB, Zhang LY, Cai WQ, Tong WD, Li FZ, Li WH. Ultrastructural abnormalities of colonic myenteric plexus in patients with slow transit constipation. Shijie Huaren Xiaohua Zazhi 1999; 7: 1049-1051
15. Tomita R, Tanjoh K, Fujisaki S, Ikeda T, Fukuzawa M. Regulation of the enteric nervous system in the colon of patients with slow transit constipation. Hepatogastroenterology 2002; 49: 1540-1544
16. Wald A. Slow transit constipation. Curr Treat Options Gastroenterol 2002; 5: 279-283
17. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002; 16: 1347-1356
18. Alaradi O, Barkin JS. Irritable bowel syndrome: Update on pathogenesis and management. Med Princ Pract 2002; 11: 2-17
19. Krogh K, Jensen MB, Gandrup P, Laurberg S, Nilsson J, Kerstens R, De Pauw M. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol 2002; 37: 431-436
20. Sloots CE, Poen AC, Kerstens R, Stevens M, De Pauw M, Van Oene JC, Meuwissen SG, Felt-Bersma RJ. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002; 16: 759-767
21. De Schryver AM, Andriesse GI, Samsom M, Smout AJ, Gooszen HG, Akkermans LM. The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 603-612
22. Kamm MA. Review article: The complexity of drug development for irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 343-351
23. Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol 2002; 97: 194-197
24. Ahn J, Ehrenpreis ED. Emerging treatments for irritable bowel syndrome. Expert Opin Pharmacother 2002; 3: 9-21
25. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001; 358: 2061-2068
26. Talley NJ. Drug therapy options for patients with irritable bowel syndrome. Am J Manag Care 2001; 7(8 Suppl): S261-S267
27. De Ponti F, Tonini M. Irritable bowel syndrome: New agents targeting serotonin receptor subtypes. Drugs 2001; 61: 317-332
28. De Schryver AM, Samsom M. New developments in the treatment of irritable bowel syndrome. Scand J Gastroenterol Suppl 2000; 232: 38-42
29. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 354-360
30. Scarpignato C, Pelosini I. Management of irritable bowel syndrome: Novel approaches to the pharmacology of gut motility. Can J Gastroenterol 1999; 13(Suppl A): 50A-65A
31. Zhu JZ. New development of the gastrointestinal prokinetic agents. Xin Xiaohua Bingxue Zazhi 2001; 9: 1439-1444
32. Zhu JZ, Yang GH, Leng ER, Chen DF. Gastrointestinal motility promoting action of traditional Chinese medicine. Shijie Huaren Xiaohua Zazhi 1999; 7: 689-690